All the news Showing 10 of 71 articles from: HIVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection Liz Highleyman / 04 March 2015 A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis C for more than 95% of ... People living with HIV have high survival rates after liver transplants due to HCC Keith Alcorn / 12 November 2014 People with HIV – most of whom had hepatitis B or C co-infection – generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with five-year survival rates similar to those ... Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection Liz Highleyman / 10 November 2014 All but one participant treated for hepatitis C virus (HCV) with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment, in a study involving people with ... People living with HIV in the US are infrequently screened for HCV Michael Carter / 24 September 2014 People living with HIV are infrequently screened for hepatitis C virus (HCV) infection, according to US research published in the online edition of Clinical Infectious Diseases. The retrospective study examined screening practices ... Even moderate drinking increases risk of advanced liver fibrosis for people with HIV and HCV co-infection Michael Carter / 28 May 2014 Even moderate alcohol consumption is associated with an increased risk of advanced liver fibrosis for people living with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in Clinical ... MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection Liz Highleyman / 11 April 2014 Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus ... Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection Liz Highleyman / 14 November 2013 The hepatitis C protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to a ... Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people Liz Highleyman / 08 November 2013 An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured hepatitis C infection in three quarters of previously untreated HIV-positive people co-infected with hepatitis C virus (HCV) genotype 1, while ... High response rates with telaprevir triple therapy for HIV-positive men with acute hepatitis C Liz Highleyman / 05 November 2013 Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and improves sustained response rates for HIV-positive men with acute hepatitis C virus (HCV) infection, according to ... ← Prev1...34567...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive